Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide vs mealtime insulin aspart added to insulin degludec + metformin in type 2 diabetes
2011-001493-25Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c (%) after 26 weeks of treatment. Started May 2011; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-001493-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001493-25.